• Thurs news: Novartis not joining weight loss race. Pharma marketing and climate change. Roche flu treatment trial. Cercle’s fund raise for women’s health. ICER looks at GSK COPD drugs. See more on our front page

Regeneron's high-dose Eylea shows staying power as company awaits FDA decision

Quote
cafead

cafead

Administrator
Staff member
  • cafead   Aug 10, 2023 at 09:52: PM
via As Regeneron anxiously awaits an FDA decision on a high-dose version of Eylea (aflibercept), the company has continually referred to its durability compared to that of Roche’s upstart Vabysmos—which has taken the macular degeneration (AMD) market by storm since receiving approval 19 months ago.

article source
 

<



Similar threads

cafead
Regeneron touts launch of high-dose Eylea in battle with Roche&#039;s Vabysmo
Replies
0
Views
83
Pharma/Biotech Companies - In the News
cafead
cafead
cafead
Regeneron&#039;s high-dose Eylea hit with surprise FDA rejection over manufacturing hiccups
Replies
0
Views
267
Pharma/Biotech Companies - In the News
cafead
cafead
cafead
Sanofi and Regeneron&#039;s high-flying Dupixent tops May pharma TV spending, trading...
Replies
0
Views
227
Pharma/Biotech Companies - In the News
cafead
cafead
cafead
Regeneron&#039;s Evkeeza shows promise in curbing high triglycerides, but will genetic...
Replies
0
Views
160
Pharma/Biotech Companies - In the News
cafead
cafead
cafead
Regeneron joins Koneksa Parkinson&#039;s digital biomarker study
Replies
0
Views
10
Pharma/Biotech Companies - In the News
cafead
cafead
Top Bottom
Back
Quote